Two thirds of potentially eligible participants chose to participate, higher than seen in other studies.[31] This perhaps reflects both the burden of need amongst stroke survivors and their carers, and willingness to explore the potential of drugs to improve outcome after stroke.[32] It was feasible to deliver the drug G-CSF in the community, and G-CSF was, on the whole, well tolerated. This evidence concerns the gene CSF3 and stroke disorder.